Quantbot Technologies LP bought a new stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,218 shares of the company's stock, valued at approximately $549,000.
A number of other hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Harrow by 1.2% in the first quarter. Vanguard Group Inc. now owns 1,829,805 shares of the company's stock worth $24,208,000 after acquiring an additional 21,253 shares during the period. Oppenheimer & Co. Inc. bought a new position in shares of Harrow during the third quarter valued at approximately $1,267,000. Penserra Capital Management LLC purchased a new position in Harrow during the third quarter valued at approximately $1,986,000. SG Americas Securities LLC bought a new position in Harrow in the third quarter worth approximately $534,000. Finally, Semanteon Capital Management LP purchased a new stake in Harrow during the third quarter worth $686,000. Institutional investors own 72.76% of the company's stock.
Harrow Trading Down 5.4 %
Shares of HROW stock traded down $2.25 during mid-day trading on Tuesday, reaching $39.61. The stock had a trading volume of 265,272 shares, compared to its average volume of 509,440. Harrow, Inc. has a 1-year low of $9.13 and a 1-year high of $59.23. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The business's fifty day moving average is $47.56 and its 200-day moving average is $34.87.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on HROW shares. Lake Street Capital raised their price objective on Harrow from $45.00 to $55.00 and gave the company a "buy" rating in a research report on Friday, October 4th. B. Riley reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Harrow in a research report on Thursday, August 29th. Finally, Craig Hallum increased their target price on shares of Harrow from $45.00 to $65.00 and gave the company a "buy" rating in a research report on Friday, October 4th.
Get Our Latest Stock Analysis on HROW
Harrow Company Profile
(
Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Read More
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
